HeraMEDASX:HMD -2.63% Days Payable is 0.00 as of Dec. 2025. The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, HeraMED ranks worse than 125786.04% on this metric.
The historical rank and industry rank for HeraMED's Days Payable or its related term are showing as below:
During the past 8 years, HeraMED's highest Days Payable was 5786.59. The lowest was 1276.54. And the median was 1894.22.
ASX:HMD's Days Payable is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 68.07 * Ranked among companies with meaningful Days Payable only.
HeraMED's Days Payable
declined
from Dec. 2024 (1,586.47) to Dec. 2025 (0.00).
It may suggest that HeraMEDaccelerated paying its suppliers.
HeraMED Days Payable Related Terms
HeraMED Days Payable Historical Data
* Premium members only.
The historical data trend for HeraMED's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, HeraMED's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeraMED Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's Days Payable distribution charts can be found below:
* The bar in red indicates where HeraMED's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
HeraMED's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeraMED (ASX:HMD) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HeraMED and its competitors. Over the past decade, HeraMED's Days Payable has ranged from 1,276.54 to 5,786.59. According to the industry distribution chart, HeraMED ranks #999999 out of 795 companies in the Medical Devices & Instruments industry.
Is HeraMED's Days Payable too high?
HeraMED's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,276.54 to a high of 5,786.59. Based on the distribution chart, HeraMED ranks #999999 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does HeraMED's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HeraMED ranks #999999 out of 795 companies for Days Payable. This places HeraMED in the lower half of its industry. The industry median Days Payable is 68.07. Historically, HeraMED's own Days Payable has ranged from 1,276.54 to 5,786.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HeraMED and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeraMED's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.04 — trading 85% above its estimated fair value. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HMD has been successfully added to your 